Purchase this article with an account.
Jose A Cardillo, Murilo Wendeborn Rodrigues, Leticia Fernandes Barroso, Rubens C Siqueira, Rodrigo Jorge; The Sympatholytic Non-selective β-blocker PROPRANOLOL as A Non-invasive Therapeutic Approach for the Treatment of Chronic Central Serous Chorioretinopathy (CSC). Invest. Ophthalmol. Vis. Sci. 2014;55(13):6380.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of systemically administered β-blocker propranolol on the course of central serous chorioretinopathy. Our goal is to research potential alternative tool for chronic CSC as monotherapy or as adjunct to more invasive laser techniques
Fourteen CSC-patients with a documented-persistent leakage of at least 4 months were treated by oral propranolol 20 mg twice a day and followed up at monthly intervals for 6 months. Best-corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICGA), central macular thickness (CMT) quantified by ocular coherence tomography (OCT), were recorded at baseline and follow-up visits
At 3 months, BCVA was significantly enhanced in the treatment group (P =.006) compared with baseline. An improvement in central macular thickness and leakage on fluorescein angiography was noted in all treated patients starting as early as 30 days following treatment
β-blocker has a plausible mechanism of action in CSC and may characterize a potential alternative to the present standard of care meriting further evaluation.
This PDF is available to Subscribers Only